title: Harm reduction at the crossroads: the case of e-cigarettes.
abstract: The recent popularity of electronic (e)-cigarettes and their rapid uptake by youth has ignited the debate about their role as a harm-reduction strategy. Harm reduction in the context of tobacco control contends that in societies that have achieved considerable success in curbing smoking, leaving the remaining hard-to-quit smokers with an abstinence-only option is unfair, especially when less-harmful choices are available. On one side of the debate are those who call for caution in endorsing such products until critical pieces of evidence about their safety and potential become available, whereas the other side argues that waiting until all questions about e-cigarettes are answered is dogma driven. In this piece, I try to discuss the unresolvable contention between harm-reduction goals of offering safer options to smokers, and those of e-cigarette makers of being commercially viable and profitable.
authors.affiliation: Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, Florida; and Syrian Center for Tobacco Studies, Aleppo, Syria. Electronic address: wmaziak@fiu.edu.
authors.forename: Wasim
authors.initials: W
authors.lastname: Maziak
mesh_terms: D000293:Adolescent; D003132:Commerce / Q000191:economics; D066300:Electronic Nicotine Delivery Systems / Q000009:adverse effects / Q000191:economics / Q000706:statistics & numerical data*; D040261:Harm Reduction; D006801:Humans; D016540:Smoking Cessation / Q000379:methods; D000074606:Smoking Prevention
references.citation: BMJ. 2013 Sep 26;347:f5780
references.pmid: 24070876
references.citation: Pediatrics. 2005 Dec;116(6):1516-28
references.pmid: 16322180
references.citation: MMWR Morb Mortal Wkly Rep. 2013 Sep 6;62(35):729-30
references.pmid: 24005229
references.citation: Lancet. 2013 Nov 16;382(9905):1614-6
references.pmid: 24029168
references.citation: Lancet Respir Med. 2013 Sep;1(7):e26
references.pmid: 24461619
references.citation: Int J Drug Policy. 2007 Mar;18(2):70-4
references.pmid: 17689347
references.citation: Lancet Respir Med. 2013 Aug;1(6):429-31
references.pmid: 24429230
references.citation: Tob Control. 2013 May;22 Suppl 1:i33-5
references.pmid: 23591504
references.citation: Health Educ Behav. 2014 Jun;41(3):275-80
references.pmid: 24347143
references.citation: Addiction. 2012 Sep;107(9):1545-8
references.pmid: 22471757
references.citation: Arch Pediatr Adolesc Med. 2007 Jul;161(7):704-10
references.pmid: 17606835
references.citation: Addiction. 2003 May;98 Suppl 1:37-55
references.pmid: 12752361
references.citation: BMJ. 2013 Jun 14;346:f3845
references.pmid: 23771039
references.citation: N Engl J Med. 2014 Jan 23;370(4):293-5
references.pmid: 24350902
references.citation: J Public Health Policy. 2011 Feb;32(1):16-31
references.pmid: 21150942
references.citation: Lancet. 2013 Nov 16;382(9905):1629-37
references.pmid: 24029165
references.citation: Addict Behav. 2014 Mar;39(3):507-11
references.pmid: 24290207
references.citation: Tob Control. 2011 Nov;20(6):425-6
references.pmid: 21659450
references.citation: JAMA. 2014 Jan 8;311(2):135-6
references.pmid: 24399548
references.citation: Lancet Oncol. 2014 Mar;15(3):e104
references.pmid: 24599927
references.citation: Lancet Respir Med. 2013 Nov;1(9):678
references.pmid: 24429266